scPharmaceuticals Inc. Announces Resubmission of FUROSCIX® New Drug Application
scPharmaceuticals (Nasdaq: SCPH) has resubmitted its New Drug Application (NDA) for FUROSCIX, aimed at treating decompensated heart failure. The FDA review is anticipated to conclude by Q4 2022, contingent on approval. The company reported that West Pharmaceutical Services has also completed development of related support documentation. CEO John Tucker highlighted the importance of this milestone and noted the promising cost-saving data from the FREEDOM-HF study, suggesting potential market success if approved.
- Resubmission of the FUROSCIX NDA marks a significant milestone for scPharmaceuticals.
- FREEDOM-HF study shows promising cost-saving data, enhancing approval prospects.
- The potential outcomes from the FDA review remain uncertain and could be subject to delays.
- Market success is reliant on FDA approval and subsequent commercialization efforts.
Anticipates Q4 2022 commercial launch, if approved
BURLINGTON, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the company has resubmitted its New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking marketing approval for FUROSCIX for the treatment of decompensated heart failure. In addition, West Pharmaceutical Services, Inc. has completed all development activities and submitted the Device Master File in support of the FUROSCIX NDA.
“The resubmission of the FUROSCIX NDA is a major milestone for our company as it is an important landmark in our transition to a commercial stage company, if approved,” stated John Tucker, chief executive officer of scPharmaceuticals. “Our clinical data package, together with the compelling cost savings recently observed in our FREEDOM-HF study, give us a high degree of conviction that, if approved, FUROSCIX could become a valuable therapy for the treatment of worsening heart failure due to congestion pre-hospital admission and/or post-discharge.”
The company is advancing its commercial readiness activities in anticipation of a potential Q4 commercial launch, if approved. These include:
- Finalizing physician, payer and pricing research;
- Communicating FUROSCIX data, including FREEDOM-HF data, to pharmacy benefit managers and health plans through its product dossier;
- Finalizing FUROSCIX distribution partners; and
- Reinitiating commercial staffing to support anticipated Q4 2022 launch, if approved.
About FUROSCIX® (furosemide injection) for subcutaneous injection
FUROSCIX is an investigational, proprietary furosemide solution formulated to a neutral pH, designed to allow for subcutaneous infusion via a wearable, pre-programmed on-body drug delivery system, for outpatient self-administration. FUROSCIX is currently under development for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization. If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the timing and outcome of the FDA review process, the significance and potential impact of the results of the FREEDOM-HF clinical trial and the clinical data; the Company’s planned efforts to prepare for commercialization of FUROSCIX; and the commercial success of FUROSCIX, if approved. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the risk of the ability of the FUROSCIX On-Body Infusor to appropriately deliver therapy, the receipt of regulatory approval for the FUROSCIX On-Body Infusor or any of our other product candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates, and the risk that the current COVID-19 pandemic will impact the Company’s device validation, drug stability testing, and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2021 on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com
Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com
FAQ
What is the status of scPharmaceuticals' FUROSCIX NDA as of April 2022?
When is scPharmaceuticals anticipating a commercial launch of FUROSCIX?
What are the results of the FREEDOM-HF study related to FUROSCIX?
Who completed the Device Master File in support of the FUROSCIX NDA?
What patient population is FUROSCIX intended to treat?
